CD56-Targeting Antibody-Drug Conjugates for Neuroblastoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for CD56-positive cancers lack effective targeting and internalization mechanisms, limiting the efficacy of antibody-drug conjugates (ADCs) in reducing tumor growth and metastasis.
Innovation Solution
Development of human monoclonal antibodies (m900 and m906) that specifically bind to CD56, with ADCs conjugated to cytotoxic agents, enabling targeted delivery and internalization in CD56-positive cancer cells, utilizing spatially separated epitopes to induce down-regulation and internalization of CD56, and mediating antibody-dependent cellular cytotoxicity (ADCC).
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional ADCs are used for treating CD56-positive cancers, then the treatment can be administered, but the efficacy is limited due to lack of effective targeting and internalization mechanisms
Solution Approach 1:
The patent applies local quality by targeting specific spatially separated epitopes on the CD56 protein. The first antibody targets the N-terminal IgG-like domains while the second antibody targets the membrane-proximal fibronectin type III domains. This localized targeting of specific regions enhances internalization efficiency and treatment efficacy without requiring complex overall system design.
Solution Approach 2:
The patent uses CD56-specific monoclonal antibodies as intermediaries to deliver cytotoxic agents to tumor cells. The antibodies serve as mediators that bridge the cytotoxic drugs and the target cells, enabling selective delivery. The use of bispecific antibodies further enhances this intermediary function by simultaneously binding to CD56 and facilitating internalization or ADCC.
2Productivity
If ADCs are designed to target CD56, then targeted delivery is achieved, but the ability to induce internalization and ADCC is insufficient
Solution Approach 1:
The patent merges multiple functions into a single antibody structure by creating bispecific antibodies that simultaneously bind to two different epitopes on CD56. This merging of targeting and internalization induction functions into one molecule enhances tumor cell killing efficiency without requiring separate complex delivery systems.
Solution Approach 2:
The patent employs composite antibody structures combining different antibody specificities (m906 and m900) to create bispecific antibodies. This composite approach integrates the targeting capability of one antibody with the internalization-inducing capability of another, achieving enhanced productivity through structural composition rather than complex external mechanisms.
3Ease of manufacture
If single-antibody ADCs are used, then the design is simpler, but the ability to simultaneously target and induce internalization is limited
Solution Approach 1:
The patent applies partial action by using separate monoclonal antibodies for targeting and internalization induction rather than requiring a fully integrated complex system. The m906 antibody provides targeting while m900 enhances internalization, and these can be used separately or combined, allowing flexible manufacturing approaches that balance simplicity with effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ADCs effectively kill CD56-positive cancer cells by inducing internalization and ADCC, demonstrating potent cytotoxic activity and tumor regression in preclinical models, particularly in neuroblastoma cell lines.
Implementation Method 1
Human monoclonal antibodies that bind CD56, and antibody-drug conjugates (ADCs) comprising the CD56-specific antibodies are disclosed
Implementation Method 2
mediating antibody-dependent cellular cytotoxicity (ADCC)
Data Source
AI summary
The identification and characterization of two fully human CD56-specific monoclonal antibodies targeting spatially separated epitopes proximal and distal to the plasma membrane is described. Also described are antibody-drug conjugates (ADCs) of the identified antibodies and their use for targeting CD56-expressing tumor cells.